The US Food and Drug Administration’s advisory committee scheduling policy could be updated as part of an ongoing modernization initiative, potentially impacting the number of meetings that could be held.
Kevin Bugin, acting deputy director of operations in the FDA Office of New Drugs, said that because advisory committee meetings require so much work to plan, the agency is exploring...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?